Maxx Chatsko Archives - 7investing

Posts by Maxx Chatsko

Article

Maxx’s Top Stock for May 2022

May 1, 2022

7investing Lead Advisor Maxx Chatsko's top stock to buy in May 2022 serves as the linchpin of for biology-driven enterprises.

Premium Deep Dive

Twist Bioscience Deep Dive: May 2022

May 1, 2022

Premium Deep Dive

Selecta Biosciences Deep Dive: April 2022

Apr 4, 2022

Premium Deep Dive

Avita Medical Deep Dive: March 2022

Mar 1, 2022

Video

Maxx’s Top Stock for March 2022

Mar 1, 2022

7investing Lead Advisor Maxx Chatsko's top stock to buy in March 2022 is on the cusp of ramping three high-growth brands large, underserved markets.

Article

Interacting with Members and Refining My Frameworks

Feb 22, 2022

Speaking with members has helped me to fine-tune my research process with clearer communication in mind.

Premium Advisor Update

Will Solid-State Batteries Live Up to the Hype?

Feb 8, 2022

Video

Maxx’s Top Stock for February 2022

Feb 1, 2022

7investing Lead Advisor Maxx Chatsko's top stock to buy in February 2022 has what might be the best technology stack and most methodical approach in molecular testing. That makes it well positioned...

Premium Deep Dive

Exact Sciences Deep Dive: February 2022

Feb 1, 2022

Premium Advisor Update

“Very High Risk” Isn’t Very Helpful

Jan 26, 2022

Article

Wild Prediction for 2022: CRISPR Stocks Become Mortal Again

Jan 22, 2022

Emerging therapeutic modalities built on the enzymatic tool will be subject to the traditional risk-reward calculus facing drug developers.

Premium Advisor Update

Should You Invest in Synthetic Biology Stocks?

Jan 14, 2022

Podcast

5 Big Reveals from the 2022 JP Morgan Healthcare Conference

Jan 13, 2022

7investing Lead Advisors Simon Erickson and Maxx Chatsko discuss a handful of big reveals from the first few days of the 2022 JP Morgan Healthcare Conference.

Premium Deep Dive

Krystal Biotech Deep Dive: January 2022

Jan 1, 2022

Video

Maxx’s Top Stock for January 2022

Jan 1, 2022

7investing Lead Advisor Maxx Chatsko's top stock to buy in January 2022 is developing a novel technology platform that's well-positioned to address some of the biggest challenges facing gene therapy...

Article

Dicerna Pharmaceuticals Deep Dive: October 2021

Dec 28, 2021

For the first time ever, we are releasing an active recommendation to the general public as three-time recommendation Dicerna Pharmaceuticals was acquired by Novo Nordisk in a $3.3 billion deal.

Premium Advisor Update

Can Better Antibodies Disrupt Cell Therapy?

Dec 20, 2021

Podcast

Investing in Emerging Markets with Perth Tolle

Dec 16, 2021

7investing Lead Advisors Matt Cochrane and Maxx Chatsko chat with Perth Tolle about investing in emerging markets as a global citizen who respects economic and personal freedoms.

Premium Deep Dive

Selecta Biosciences Deep Dive: December 2021

Dec 1, 2021

Video

Maxx’s Top Stock for December 2021

Dec 1, 2021

7investing Lead Advisor Maxx Chatsko's top stock to buy in December 2021 has just de-risked the entire therapeutic modality of gene therapy -- and Wall Street is entirely misunderstanding the...

Article

Think Long Term, but Focus on Your Five-Meter Targets

Nov 21, 2021

Take care of business before getting too carried. Invest in companies that do the same.

Premium Advisor Update

I Choose Embarrassment

Nov 13, 2021

Premium Deep Dive

Coherus BioSciences Deep Dive: November 2021

Nov 1, 2021

Video

Maxx’s Top Stock for November 2021

Nov 1, 2021

7investing Lead Advisor Maxx Chatsko's top stock to buy in November 2021 is at the very beginning of an inflection point in its growth trajectory.

Article

Navigating Inflation and Interest Rates with Your Hard-Earned Money

Oct 22, 2021

Even long-term investors should acknowledge the role that Fed policy is playing in stock valuations.

Podcast

Blue-Sky Thinking in Synthetic Biology

Oct 19, 2021

What will it take for synthetic biology to live up to its promise? 7investing Lead Advisor Maxx Chatsko talks with visionary scientist Andrew Hessel about pushing the envelope of living technologies ...

Premium Advisor Update

Drug Development is Risky. Let’s Count the Ways.

Oct 14, 2021

Podcast

7investing Explains: How are Medical Devices and Genetic Tests Regulated?

Oct 14, 2021

Health care investors often focus on drug products, but medical devices present unique investing opportunities, too. 7investing Lead Advisors Simon Erickson, Dana Abramovitz, and Maxx Chatsko provide...

Article

Can Your Gene Editing Stocks Survive the End of Momentum?

Oct 8, 2021

There are both opportunities and challenges to modifying DNA for therapeutic applications, but objective information is scarce.

Premium Deep Dive

Dicerna Pharmaceuticals Deep Dive: October 2021

Oct 1, 2021

Video

Maxx’s Top Stock for October 2021

Oct 1, 2021

7investing Lead Advisor Maxx Chatsko's Top Stock for October 2021 is one of the most undervalued drug developers on the market.

Article

Why are $100 Billion Drug Developers Such Lousy Investments?

Sep 23, 2021

While 18 companies have crossed that valuation milestone, only one has consistently outperformed the S&P 500 after.

Article

Give Your Thesis Time to Breathe, But Be Objective

Sep 22, 2021

Knowing when to sell an early-stage drug developer isn't easy, but it's nearly impossible when you're a cheerleader.

Article

What’s Next for mRNA?

Sep 15, 2021

The therapeutic modality is well-suited to create vaccines for infectious diseases. What about other therapeutic areas?

Premium Advisor Update

Annual 2021 Review: Maxx’s 7investing Recommendations

Sep 14, 2021

Podcast

Bringing Synthetic Biology to Consumers, One Material at a Time

Sep 14, 2021

Sustainable materials might be the biggest market opportunity no one is talking about. 7investing Lead Advisor Maxx Chatsko chats with Bolt Threads CEO Dan Widmaier about the opportunities and...

Article

The FDA Cracks Down on Safety for Multiple Drug Classes

Sep 10, 2021

The moves send a clear signal to drug developers, even if the immediate economic consequences are mostly limited.

Podcast

7investing Market Focus: Why Are Investors So Optimistic? (8/24/21)

Sep 2, 2021

News that the FDA gave Pfizer (NYSE: PFE) full approval for its COVID-19 vaccine, as well as crude prices rallying caused all the major indexes to end the day in the green. Join Maxx Chatsko and...

Podcast

7investing Market Focus: Why Long-Term Investors Don’t Worry on Red…

Sep 2, 2021

If there is one thing investors can predict, it is that there will be volatility in the stock market. Stocks can plummet 20% or more in a single day on no news. While that can be frustrating, it's...

Premium Deep Dive

Exact Sciences Deep Dive: September 2021

Sep 1, 2021

Video

Maxx’s Top Stock for September 2021

Sep 1, 2021

7investing Lead Advisor Maxx Chatsko's top stock to buy in September 2021 is a leading provider of genetic and molecular testing services.

Article

What Will the Delta Variant Mean for the Stock Market?

Aug 22, 2021

Covid cases are up and that spooked some investors, but the effect may be short-lived.

Article

Repligen Always Seems to Make the Right Moves

Aug 21, 2021

The bioprocess leader quietly keeps delivering for shareholders.

Article

I Tracked Every Car-Related Expense for 8 Years. Here’s What…

Aug 18, 2021

What's the true cost of car ownership? My nerdy habit has provided some interesting answers.

Podcast

7investing Market Focus: The Red Hot Rental Market (8/11/21)

Aug 17, 2021

Low interest rates and skyrocketing housing prices have been raising the roof on the rental market. What impact will this have on the overall US economy? 7investing lead advisors Dan Kline and Maxx...

Premium Advisor Update

What Defines a Stock Market Bubble?

Aug 13, 2021

Article

Will We Need a Covid Vaccine Booster Shot?

Aug 13, 2021

The companies that make the shot say yes, but the answer is more complicated.

Podcast

7investing Market Focus: Simon’s Malls Are Returning Back to Normal…

Aug 10, 2021

Simon Property Group has disclosed its sales have now fully recovered to their 2019 levels. Post-pandemic, what items are consumers most interested in buying from malls? 7investing lead advisors Dan...

Advisor Update

The 7investing Recommendation That Wasn’t

Aug 9, 2021

Maxx explains how red flags prevented him from recommending a seemingly promising biopharma stock to 7investing subscribers.

Podcast

The 3 Frameworks for Evaluating Gene Editing Stocks

Aug 3, 2021

Most investors have heard about gene editing, but there are many differences between the major technology platforms. 7investing Lead Advisors Maxx Chatsko and Dan Kline introduce three simple...